First-Ever custom RNA vaccines tested in breast cancer patients
NCT ID NCT02316457
Summary
This early-stage trial tested two personalized RNA vaccines designed to train the immune system to fight triple-negative breast cancer. The study involved 42 patients who received vaccines tailored to their specific tumor characteristics. Researchers aimed to determine if these custom vaccines were safe and could stimulate an immune response against cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER (TRIPLE NEGATIVE BREAST CANCER (TNBC)) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dr. Horst Schmidt-Kliniken Wiesbaden
Wiesbaden, 65199, Germany
-
Johannes Gutenberg University
Mainz, RLP, 55131, Germany
-
National Center for Tumor Diseases (NCT)
Heidelberg, 69120, Germany
-
Uppsala University Hospital
Uppsala, 75185, Sweden
Conditions
Explore the condition pages connected to this study.